Early insight into antibody-dependent enhancement after SARS-CoV-2 mRNA vaccination
Current vaccines, which induce a B-cell-mediated antibody response against the spike protein of SARS-CoV-2, have markedly reduced infection rates. However, the emergence of new variants as a result of SARS-CoV-2 evolution requires the development of novel vaccines that are T-cell-based and that targ...
Main Authors: | , , , |
---|---|
Format: | Article |
Language: | English |
Published: |
Taylor & Francis Group
2021-11-01
|
Series: | Human Vaccines & Immunotherapeutics |
Subjects: | |
Online Access: | http://dx.doi.org/10.1080/21645515.2021.1969855 |
_version_ | 1797673344056688640 |
---|---|
author | Amal Hasan Mohammad R. Al-Mulla Jehad Abubaker Fahd Al-Mulla |
author_facet | Amal Hasan Mohammad R. Al-Mulla Jehad Abubaker Fahd Al-Mulla |
author_sort | Amal Hasan |
collection | DOAJ |
description | Current vaccines, which induce a B-cell-mediated antibody response against the spike protein of SARS-CoV-2, have markedly reduced infection rates. However, the emergence of new variants as a result of SARS-CoV-2 evolution requires the development of novel vaccines that are T-cell-based and that target mutant-specific spike proteins along with ORF1ab or nucleocapsid protein. This approach is more accommodative in inducing highly neutralizing antibodies, without the risk of antibody-dependent enhancement, as well as memory CD8+T-cell immunity. |
first_indexed | 2024-03-11T21:43:11Z |
format | Article |
id | doaj.art-f0461e560bde47c7a454c443b46dbd49 |
institution | Directory Open Access Journal |
issn | 2164-5515 2164-554X |
language | English |
last_indexed | 2024-03-11T21:43:11Z |
publishDate | 2021-11-01 |
publisher | Taylor & Francis Group |
record_format | Article |
series | Human Vaccines & Immunotherapeutics |
spelling | doaj.art-f0461e560bde47c7a454c443b46dbd492023-09-26T12:43:41ZengTaylor & Francis GroupHuman Vaccines & Immunotherapeutics2164-55152164-554X2021-11-0117114121412510.1080/21645515.2021.19698551969855Early insight into antibody-dependent enhancement after SARS-CoV-2 mRNA vaccinationAmal Hasan0Mohammad R. Al-Mulla1Jehad Abubaker2Fahd Al-Mulla3Dasman Diabetes InstituteKuwait UniversityDasman Diabetes InstituteDasman Diabetes InstituteCurrent vaccines, which induce a B-cell-mediated antibody response against the spike protein of SARS-CoV-2, have markedly reduced infection rates. However, the emergence of new variants as a result of SARS-CoV-2 evolution requires the development of novel vaccines that are T-cell-based and that target mutant-specific spike proteins along with ORF1ab or nucleocapsid protein. This approach is more accommodative in inducing highly neutralizing antibodies, without the risk of antibody-dependent enhancement, as well as memory CD8+T-cell immunity.http://dx.doi.org/10.1080/21645515.2021.1969855sars-cov-2covid-19antibody-dependent enhancementneutralizationantibodiesvaccinespike protein |
spellingShingle | Amal Hasan Mohammad R. Al-Mulla Jehad Abubaker Fahd Al-Mulla Early insight into antibody-dependent enhancement after SARS-CoV-2 mRNA vaccination Human Vaccines & Immunotherapeutics sars-cov-2 covid-19 antibody-dependent enhancement neutralization antibodies vaccine spike protein |
title | Early insight into antibody-dependent enhancement after SARS-CoV-2 mRNA vaccination |
title_full | Early insight into antibody-dependent enhancement after SARS-CoV-2 mRNA vaccination |
title_fullStr | Early insight into antibody-dependent enhancement after SARS-CoV-2 mRNA vaccination |
title_full_unstemmed | Early insight into antibody-dependent enhancement after SARS-CoV-2 mRNA vaccination |
title_short | Early insight into antibody-dependent enhancement after SARS-CoV-2 mRNA vaccination |
title_sort | early insight into antibody dependent enhancement after sars cov 2 mrna vaccination |
topic | sars-cov-2 covid-19 antibody-dependent enhancement neutralization antibodies vaccine spike protein |
url | http://dx.doi.org/10.1080/21645515.2021.1969855 |
work_keys_str_mv | AT amalhasan earlyinsightintoantibodydependentenhancementaftersarscov2mrnavaccination AT mohammadralmulla earlyinsightintoantibodydependentenhancementaftersarscov2mrnavaccination AT jehadabubaker earlyinsightintoantibodydependentenhancementaftersarscov2mrnavaccination AT fahdalmulla earlyinsightintoantibodydependentenhancementaftersarscov2mrnavaccination |